Business
Canalevia-CA1, Jaguar Animal Health’s FDA Conditionally Approved Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs, Now Available from Chewy
Canalevia®-CA1 is the first and only treatment for CID in dogs to receive any type of approval from the FDASAN FRANCISCO, CA / ACCESSWIRE / May 11, 2023 /
About this update from Jaguar Health, Inc.
[{"type":"text","content":"Canalevia®-CA1 is the first and only treatment for CID in dogs to receive any type of approval from the FDASAN FRANCISCO, CA / ACCESSWIRE / May 11, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) (\"Jaguar\" or the \"Company\") under its Jaguar Animal Health tradename for the veterinary market, today announced that Canalevia-CA1 (crofelemer delayed-release tablets), the company's U.S. Food and Drug Administration (FDA) conditionally approved prescription drug product for the treatment of chemotherapy-induced diarrhea (CID) in dogs, is now available on Chewy, a trusted destination for pet parents and partners everywhere. \"We are thrilled to have added Chewy to the list of prominent pet retailers in the U.S. that offer Canalevia-CA1. Chewy's award-winning customer service and fast and reliable shipping will provide additional ease, convenience and support for pet parents who are navigating cancer treatments for their pets,\" said Ian Wendt, Jaguar's Chief Commercial Officer. About Chemotherapy-induced Diarrhea (CID) in DogsDue to the increasing number of chemotherapeutic agents being adopted by veterinary oncologists and primary care veterinarians, chemotherapy is fast becoming the most widely used cancer treatment in veterinary medicine. Studies have found the incidence of CID to be one of the three most prevalent side effects in dogs undergoing cancer treatment,1 and managing side-effects such as diarrhea can be important to maintain successful cancer treatment. More than half of the U.S. veterinarians who responded to a Jaguar-sponsored survey reported that CID interferes with their patients' chemotherapy treatment plans, indicating an unmet need for an effective product for the treatment of CID.About Canalevia®-CA1Canalevia-CA1 (crofelemer delayed-release tablets) is the first and only oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea (CID) in dogs. Canalevia-CA1 is a canine-specific formulation of crofelemer, an active pharmaceutical ingredient isolated and purified from the Croton lechleri tree. Canalevia-CA1 is currently conditionally approved by the FDA under application number 141-552. Conditional approval allows for commercialization of the product while Jaguar continues to collect the substantial evidence of effectiveness required for a full approval. Jaguar has re...